Follow us on Twitter @RDPHoldings
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gonna keep buying this til the wheels fall off.
Been tracking TRTC since the days of .0001. I tried to warn people about this scam company, but there were does who pumped this company and many people fell for it. Pumpers should burn in hell for the confusion they create.
If you can precisely pick stocks....why are you here begging me to click on your website for a subscribers?
Taking a position in this one for a quick flip.
Great!
Another Pejorative whose profit is an hoodwinked investors lost.
So True. Because of laws, government, committees, SEC, courts....etc. Investors are equipped to hold criminal CEO’s and Corporate Entities responsible for their outright criminal activities.
It’s both criminal and sinful how Terra Tech has lured unsuspecting investors and stripped them of their cash and time. I’m on board for a class action lawsuit.
Looks like S3 released a few minutes ago. More dilution.
I think the countdown clock on the company website is a pump and dump ta tic. But just in case something positive comes from this circus act...I picked up a million.
We have entered into some sort of Twilight zone with MTVX....please remain calm and gather your senses.
This company is perhaps the worst investment in the history of the known universe!
100,000,000,000 authorized shares
40,000,000,000 already issued
60,000,000,000 left to dump before massive reverse split
Conference Call today @ 4:30 EST.
Right now...I'm thinking TRTC will bring my brand new 2016 Tesla.
CC 2 pm today?....which time zone?
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10126427.htm
Results Anticipated in Third Quarter 2015, Positioning Zogenix for Potential World-Wide Partnering Opportunities for Relday
March 26, 2015: 09:00 AM ET
SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that dosing has begun in patients enrolled in its Reldayâ„¢ multi-dose Phase 1b clinical study. Relday is a proprietary, long-acting, subcutaneously injected formulation of risperidone being investigated for the treatment of schizophrenia.
Relday has been designed to provide potentially significant improvements over current long-acting injection treatment options for patients suffering from schizophrenia. In a Phase 1 single-dose clinical study in schizophrenic patients, Relday demonstrated the ability to achieve therapeutic plasma levels of risperidone on the first day of dosing, followed by a controlled release profile over the remaining four-week period. This pharmacokinetic profile of Relday may eliminate the requirement for long-acting risperidone injections to be supplemented with daily oral therapy for several weeks during therapy initiation or when patients are not fully compliant with an injection regimen over the course of long-term therapy. In addition, dose-proportionality for Relday has been established across all doses, as well as the duration of treatment being consistent with once-monthly dosing. Unlike all currently marketed long-acting injectable treatment options which are administered via intramuscular injection, Relday is administered subcutaneously. Moreover, unlike some leading injectable products in the category, Relday does not require reconstitution prior to use.
Fifty-six subjects with schizophrenia or schizoaffective disorder are planned to be enrolled in this open label, multi-dose, safety and pharmacokinetic (PK) study. Subjects will be administered Relday or Risperdal® Consta® (risperidone), an approved long-acting intramuscular injectable with the same active ingredient as Relday. Patients being administered Risperdal Consta will also receive daily oral risperidone supplementation during a three-week initiation period, and will be dosed every two weeks, as required by its prescribing label. Subjects will be followed for up to 20 weeks in order to confirm and compare the time to reach drug concentrations within the therapeutic range and to compare steady state pharmacokinetics for Relday and Risperdal Consta. The Company anticipates that results from the Relday multi-dose study will be available in the third quarter of 2015.
The Company also plans to initiate efforts to secure an ex-U.S. strategic development and commercialization partner for Relday during this development stage and is targeting an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by early 2016. If completed, these milestones would position the Company to begin a Phase 3 clinical study for Relday in 2016.
Brad Galer, M.D., chief medical officer of Zogenix, stated, "We are pleased to move the Relday development program forward into this next clinical study. We expect the data to continue to demonstrate that Relday's novel formulation has a differentiated product profile amongst currently marketed long-acting injections for the treatment of schizophrenia that should enhance the treatment for this patient population."
In July 2011, Zogenix licensed from DURECT (Nasdaq:DRRX) exclusive global rights to develop and commercialize this proprietary formulation which utilizes DURECT's SABER® depot technology.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning.
Forward Looking Statements
Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding: delivery and dosing benefits of Relday and the potential to demonstrate that Relday has a differentiated product profile amongst currently marketed long-acting injections; timing for the availability of results from the Phase 1b clinical trial, an end-of-Phase 2 meeting with the FDA, and the initiation of a Phase 3 clinical trial for Relday; and the initiation of efforts to secure potential partners for rest-of-world development and commercialization of Relday. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix's business, including, without limitation: the uncertainties associated with the clinical development and regulatory approval of product candidates such as Relday, including potential delays in enrollment and completion of clinical trials; competition from other pharmaceutical or biotechnology companies; inadequate therapeutic efficacy or unexpected adverse side effects relating to Relday that could prevent its development or commercialization; difficulties in identifying, negotiating, executing and carrying out strategic transactions relating to Relday; the terms of any development or commercialization partnership for Relday may not be favorable, and the partner may not perform as expected; the market potential for anti-psychotics, and Zogenix's ability to compete within that market; Zogenix's ability to obtain, and the validity and duration of, patent protection and other intellectual property rights for Relday; and other risks described in Zogenix's prior press releases as well as in public periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Reldayâ„¢ is a trademark of Zogenix, Inc.
SABER® is a registered trademark of DURECT Corporation.
Risperdal® Consta® is a registered trademark of Janssen Pharmaceuticals, Inc.
CONTACT: Investors
Zack Kubow, The Ruth Group
646.536.7020, zkubow@theruthgroup.com
Top of page
More Markets
Stocks: 4 things to know before the open
Dow tumbles 292 points as economy shows cracks
Meet the sisters who shattered the CEO glass ceiling
Top Stories
Warning signs in the housing market
Stocks: 4 things to know before the open
These sisters shattered the CEO glass ceiling
University of Phoenix just lost half its students
What's holding back middle-class kids
Contact Us
Advertise with Us
User Preferences
Closed Captioning
Content
Business
Markets
Investing
Economy
Tech
Personal Finance
Small Business
Luxury
Media
Video
Tools
Site Map
Interactive
Portfolio
Job Search
Real Estate Search
Loan Center
Calculators
Corrections
Market Data Alerts
News Alerts
Connect
My Account
Mobile Site & Apps
Facebook
Twitter
LinkedIn
YouTube
RSS Feeds
Newsletters
Google+
Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2015 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2015. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.
© 2015 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy. .
Upcoming catalyst for MEI Pharma (odds: 90%)
2015-03-18
MEI Pharma (NASDAQ:MEIP) will report topline data from the Phase II trial (MEI-003) of pracinostat plus azacitidine in first-line myelodysplastic syndrome (MDS) in March 2015. I strongly believe the results will be positive.
Pracinostat (SB939) is a HDAC inhibitor discoved by S*Bio. MEI Pharma acquired the compound for $75.7 million in Augest 2012. The FDA has approved three HDAC inhibitors, known as Zolinza (vorinostat), Istodax (romidepsin) and Beleodaq (belinostat), for the treatment of PTCL. MEI Pharma is testing pracinostat in three Phase II trails: (1) first-line MDS (MEI-003); (2) AML (MEI-004); (3) 2nd-line MDS (MEI-005).
In the earlier pilot Phase II trial, pracinostat plus azacitidine showed an ORR of 89% (8/9) including 78% patients who achieved CR/CRi. Historical ORR for Vidaza (azacitidine) in MDS is only 16%[1]. These data led to a new Phase II trial (MEI-003) evaluating pracinostat plus azacitidine vs. placebo plus azacitidine with a primary endpoint of CR.
I believe pracinostat plus azacitidine will demonstrate a huge improvement over azacitidine alone. Forthermore, interim analysis from the MEI-005 trial revealed an ORR of 3/28 in patients who have previously failed azacitidine or decitabine alone. This data in refractory MDS further proves pracinostat’s impressive clinical efficacy.
Approximately 13,000 patients in the U.S. are diagnosed with MDS each year. Cowen and Company analyst Nicholas Bishop expects pracinostat to generate sales of $500 million or more in MDS. According to TipRanks, the average price target for MEIP is $12.83.
https://yixiblog.wordpress.com/2015/03/18/upcoming-catalyst-for-mei-pharma-odds-90/
If I earned a dollar each time I heard that, I could quit my job.
What if some brain waves were melevolent? Would this gadget have some sort of kill switch? I wouldn't want someone's brainwaves hacking my computer or cell phone.
Absolutely! Just imagine how this gadget will revolutionize the world as we know it. Giving us the ability to manipulate the physical world by the power of brain waves and all that for under $200. Absolutely astounding!!
I'm actually glad I sold. Might buy back in after the pumping and it dips
Dilution + Fake PRs= Class Action Lawsuit
Got me some :)
Looks like dilution to me
No harm intended. Im humored by the strong reactions when a stock moves up 1 or 2 clicks. Ex: praise god, to da moon, now passing orions belt, sweet baby Jesus...
Lmao@praise god.
GET MONEY TAKE MONEY, FAKE MONEY AINT MONEY :)
It means a possible short squeeze coming.
Not sure if anyone posted this...but
Reg SHO threshold list - TRTC
http://www.nasdaqtrader.com/trader.aspx?id=RegSHOThreshold
GET MONEY TAKE MONEY, FAKE MONEY AINT MONEY :)